{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:02:29Z","timestamp":1749182549150,"version":"3.41.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"DOI":"10.7759\/cureus.85373","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T03:18:36Z","timestamp":1749093516000},"source":"Crossref","is-referenced-by-count":0,"title":["Tacrolimus Ophthalmic Suspension Can Be an Effective Treatment Option for Biologic-Induced Refractory Conjunctivitis"],"prefix":"10.7759","author":[{"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Iozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69283-0","article-title":"ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys","volume":"368","author":"Asher MI","year":"2006","unstructured":"Asher MI, Montefort S, Bj\u00f6rkst\u00e9n B, Lai CK, Strachan DP, Weiland SK, Williams H. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006, 368:733-43. 10.1016\/S0140-6736(06)69283-0","journal-title":"Lancet"},{"key":"ref2","article-title":"Overview of atopic dermatitis","volume":"23","author":"Avena-Woods C","year":"2017","unstructured":"Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017, 23:115-23.","journal-title":"Am J Manag Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska J","year":"2021","unstructured":"Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021, 22:10.3390\/ijms22084130","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011040","article-title":"Filaggrin mutations associated with skin and allergic diseases","volume":"365","author":"Irvine AD","year":"2011","unstructured":"Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011, 365:1315-27. 10.1056\/NEJMra1011040","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948156","article-title":"Biologicals targeting type 2 immunity: lessons learned from asthma, chronic urticaria and atopic dermatitis","volume":"49","author":"Cosmi L","year":"2019","unstructured":"Cosmi L, Maggi L, Mazzoni A, Liotta F, Annunziato F. Biologicals targeting type 2 immunity: lessons learned from asthma, chronic urticaria and atopic dermatitis. Eur J Immunol. 2019, 49:1334-43. 10.1002\/eji.201948156","journal-title":"Eur J Immunol"},{"key":"ref6","article-title":"IL-4 and IL-13 inhibition in atopic dermatitis","volume":"15","author":"Matsunaga MC","year":"2016","unstructured":"Matsunaga MC, Yamauchi PS. IL-4 and IL-13 inhibition in atopic dermatitis. J Drugs Dermatol. 2016, 15:925-9.","journal-title":"J Drugs Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner PM","year":"2017","unstructured":"Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017, 139:S65-76. 10.1016\/j.jaci.2017.01.011","journal-title":"J Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki T","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019, 143:1-11. 10.1016\/j.jaci.2018.10.032","journal-title":"J Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.1002","article-title":"New mechanism underlying IL-31-induced atopic dermatitis","volume":"141","author":"Meng J","year":"2018","unstructured":"Meng J, Moriyama M, Feld M, et al.. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol. 2018, 141:1677-1689.e8. 10.1016\/j.jaci.2017.12.1002","journal-title":"J Allergy Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: from mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch G","year":"2018","unstructured":"Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018, 142:1375-90. 10.1016\/j.jaci.2018.09.005","journal-title":"J Allergy Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18643","article-title":"The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group","volume":"182","author":"Alexander H","year":"2020","unstructured":"Alexander H, Paller AS, Traidl-Hoffmann C, et al.. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol. 2020, 182:1331-42. 10.1111\/bjd.18643","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910381","article-title":"From emollients to biologicals: targeting atopic dermatitis","volume":"22","author":"Salvati L","year":"2021","unstructured":"Salvati L, Cosmi L, Annunziato F. From emollients to biologicals: targeting atopic dermatitis. Int J Mol Sci. 2021, 22:10.3390\/ijms221910381","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13809","article-title":"Management of dupilumab-associated conjunctivitis in atopic dermatitis","volume":"17","author":"Aszodi N","year":"2019","unstructured":"Aszodi N, Thurau S, Seegr\u00e4ber M, de Bruin-Weller M, Wollenberg A. Management of dupilumab-associated conjunctivitis in atopic dermatitis. J Dtsch Dermatol Ges. 2019, 17:488-91. 10.1111\/ddg.13809","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","volume":"6","author":"Wollenberg A","year":"2018","unstructured":"Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegr\u00e4ber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018, 6:1778-1780.e1. 10.1016\/j.jaip.2018.01.034","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Mennini M","year":"2017","unstructured":"Mennini M, Dahdah L, Fiocchi A. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017, 376:1090. 10.1056\/NEJMc1700366","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163495","article-title":"Cellular mechanisms and effects of IL-4 receptor blockade in experimental conjunctivitis evoked by skin inflammation","volume":"8","author":"Han H","year":"2023","unstructured":"Han H, Cummings S, Shade KC, et al.. Cellular mechanisms and effects of IL-4 receptor blockade in experimental conjunctivitis evoked by skin inflammation. JCI Insight. 2023, 8:10.1172\/jci.insight.163495","journal-title":"JCI Insight"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304453","article-title":"Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement","volume":"98","author":"Fukushima A","year":"2014","unstructured":"Fukushima A, Ohashi Y, Ebihara N, et al.. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol. 2014, 98:1023-7. 10.1136\/bjophthalmol-2013-304453","journal-title":"Br J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner A","year":"2021","unstructured":"Bohner A, Topham C, Strunck J, et al.. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea. 2021, 40:584-9. 10.1097\/ICO.0000000000002461","journal-title":"Cornea"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14121272","article-title":"A case of refractory vernal keratoconjunctivitis showing improvement after the administration of upadacitinib for the treatment of atopic dermatitis","volume":"14","author":"Mima Y","year":"2024","unstructured":"Mima Y, Tsutsumi E, Ohtsuka T, Ebato I, Nakata Y, Kubota T, Norimatsu Y. A case of refractory vernal keratoconjunctivitis showing improvement after the administration of upadacitinib for the treatment of atopic dermatitis. Diagnostics (Basel). 2024, 14:10.3390\/diagnostics14121272","journal-title":"Diagnostics (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01453-8","article-title":"Real-world effectiveness and safety of dupilumab, tralokinumab, and upadacitinib in patients with atopic dermatitis: a 52-week international, multicenter retrospective cohort study","author":"Torres T","year":"2025","unstructured":"Torres T, Yeung J, Prajapati VH, et al.. Real-world effectiveness and safety of dupilumab, tralokinumab, and upadacitinib in patients with atopic dermatitis: a 52-week international, multicenter retrospective cohort study. Dermatol Ther (Heidelb). 2025, 10.1007\/s13555-025-01453-8","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376477-tacrolimus-ophthalmic-suspension-can-be-an-effective-treatment-option-for-biologic-induced-refractory-conjunctivitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T03:18:37Z","timestamp":1749093517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376477-tacrolimus-ophthalmic-suspension-can-be-an-effective-treatment-option-for-biologic-induced-refractory-conjunctivitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.85373","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}